Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.
Google Scholar
Thapa B, Fazal S, Parsi M, Rogers HJ Myeloproliferative Neoplasms. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC., 2025.
James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.
Google Scholar
Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep. 2009;4:33–40.
Google Scholar
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
Google Scholar
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.
Google Scholar
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.
Google Scholar
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gatterman N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.
Google Scholar
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.
Google Scholar
Saglio G, Kim D-W, Issaragrisil S, Coutre PL, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.
Google Scholar
Cortes JE, Kim D-W, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486–92.
Google Scholar
Hochhaus A, Wang J, Kim D-W, Mayer J, Yeow-Tee G, Coutre PL, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:885–98.
Google Scholar
Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome–positive leukemias. N Engl J Med. 2012;367:2075–88.
Google Scholar
Verstovsek S, Mesa RA, Gotlib J, Levy R, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.
Google Scholar
Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.
Google Scholar
Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2024;11:e729–e740.
Google Scholar
Mascarenhas J, Gerds AT, Kiladjian J-J, Dohner K, Buckley S, Smith J, et al. PACIFICA: a randomized, controlled phase 3 study of pacritinib versus physician’s choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia. Blood. 2022;140:9592–4.
Google Scholar
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401:269–80.
Google Scholar
Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022;63:694–702.
Google Scholar
Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al. SEER Cancer Statistics Review, 1975–2016, National Cancer Institute. Bethesda https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, was posted to the SEER website. 2019.
Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Rev. 2020;42:100706.
Google Scholar
Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, et al. Project confirm: accelerated drug approvals for chronic myeloid leukemia. Clin Cancer Res. 2023;29:2179–83.
Google Scholar
Penna D. New horizons in myeloproliferative neoplasms treatment: a review of current and future therapeutic options. Medicina. 2021;57:1181.
Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence – SEER Research Plus Data, 17 Registries, 2023 Sub (2000-2021) – Linked To County Attributes – Time Dependent (1990-2022) Income/Rurality, 1969–2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released 2024, based on the 2023 submission. www.seer.cancer.gov.
Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol. 2012;87:175–82.
Google Scholar
Titmarsh GJ, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, de Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89:581–7.
Google Scholar
Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, et al. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-the Surveillance, Epidemiology, and End Results Database, 2000–2019. Cancer. 2023;129:3805–14.
Google Scholar
Hu Y, Li Q, Hou M, Peng J, Yang X, Xu S. Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the Global Burden of Disease Study 2019. JCO Glob Oncol. 2021;7:1429–41.
Google Scholar
Allahverdi N, Yassin M, Ibrahim M. Environmental factors, lifestyle risk factors, and host characteristics associated with Philadelphia-negative myeloproliferative neoplasm: a systematic review. Cancer Control. 2021;28:10732748211046802.
Google Scholar
Pedersen KM, Bak M, Sørensen AL, Zwisler AD, Ellervik C, Larsen M, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study. Cancer Med. 2018;7:5796–802.
Google Scholar
Oddsson A, Kristinsson SY, Helgason H, Gudbjartsson DF, Masson G, Sigurdsson A, et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28:1371–4.
Google Scholar
Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica. 2011;96:1575–9.
Google Scholar
Boddu P, Masarova L, Verstovsek S, Strati P, Kantarijian H, Cortes J, et al. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018;97:109–21.
Google Scholar
Horvat NP, Abdallah EF, Xie Z, Ali NA, Yun S, Walker A, et al. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities. Ann Hematol. 2024;103:117–23.
Google Scholar
Vachhani P, Loghavi S, Bose P. SOHO state of the art updates and next questions | diagnosis, outcomes, and management of prefibrotic myelofibrosis. Clin Lymphoma Myeloma Leuk. 2024;24:413–26.
Google Scholar
Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008;83:359–62.
Google Scholar
Ma X, Vanasse KGJ, Selinger HA, Wang Y, Cartmel B. Prevalence of polycythemia vera and essential thrombocythemia. Blood. 2007;110:4667.
Google Scholar
Mesa RA, Mehta J, Wang H, Wang Y, Iqbal U, Neumann F, et al. Epidemiology of myeloproliferative disorders in the US—a real-world analysis. Blood. 2012;120:2834.
Google Scholar
Kantarjian H, O’Brien S, Jabbour E, García-Manero G, Quintas-Cardama A, Shah J, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–7.
Google Scholar
Vardell VA, Sobieski CE, Tantravahi SK. Trends in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Blood. 2022;140:6763–4.
Google Scholar
Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995–3001.
Google Scholar
Machherndl-Spandl S, Hannouf S, Nikoloudis A, Zach O, Strassl I, Kaynak E et al. Improved outcomes in myelofibrosis after allogeneic stem-cell transplantation in the era of ruxolitinib pretreatment and intensified conditioning regimen, single-center analysis. Cancers. 2024;16.
Masarova L, Bose P, Pemmaraju N, Daver N, Sasaki K, Chifotides HT, et al. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022;128:1658–65.
Google Scholar
Verstovsek S, Parasuraman S, Yu J, Shah A, Kumar S, Xi A, et al. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Ann Hematol. 2022;101:131–7.
Google Scholar
Salit RB, Fan X, Randolph TW. Improvement in post-transplant outcomes over four decades in patients with myelofibrosis. Transplant Cell Ther. 2026;32:S399–S400.
Google Scholar
Arora S, Vachhani P, Bose P. Investigational drugs in early phase trials for myelofibrosis. Expert Opin Investig Drugs. 2024;33:1231–44.
Google Scholar
Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, et al. JAK inhibitor selection in challenging scenarios of myelofibrosis: a review. Haematologica. 2026;111:1179–97.
Google Scholar
Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson C, et al. Gender and survival in essential thrombocythemia: a two-center study of 1494 patients. Am J Hematol. 2017;92:1193–7.
Google Scholar
Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, et al. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica. 2017;102:85–93.
Google Scholar
Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291–302.
Google Scholar
Tefferi A, Loscocco GG, Rokach L, Tadmor T, Faldu P, Melamed G, et al. Triple A plus (AAA (+)) survival prediction model for essential thrombocythemia: analysis involving 7308 patients. Am J Hematol. 2025;100:2017–27.
Google Scholar
Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120:1197–201.
Google Scholar
Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, et al. A globally applicable “triple A” risk model for essential thrombocythemia based on age, absolute neutrophil count, and absolute lymphocyte count. Am J Hematol. 2023;98:1829–37.
Google Scholar
Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, et al. 20+ Years and alive with primary myelofibrosis: phenotypic signature of very long-lived patients. Am J Hematol. 2019;94:286–90.
Google Scholar
Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010;95:1090–7.
Google Scholar
Spivak JL, Considine M, Williams DM, Talbot JrCC, Rogers O, Moliterno AR, et al. Two clinical phenotypes in polycythemia vera. N Engl J Med. 2014;371:808–17.
Google Scholar
Karantanos T, Chaturvedi S, Braunstein EM, Spivak J, Resar L, Karanika S, et al. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020;4:2567–76.
Google Scholar
Karantanos T, Gondek LP, Varadhan R, Moliterno AR, DeZern AE, Jones RJ, et al. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Br J Haematol. 2021;193:1142–50.
Google Scholar
Jolin J, Harnois M, Mollica L, Laneuville P, Delage R, Olney HJ, et al. Very elderly patients with myeloproliferative neoplasms: phenotypic distinctions and prognostic determinants of complications and mortality. Blood. 2021;138:2572.
Google Scholar
Khan I, Shergill A, Saraf SL, Chen YF, Patel PR, Quigley JG, et al. Outcome disparities in caucasian and non-caucasian patients with myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2016;16:350–7.
Google Scholar
Peseski AM, Saliba AN, Althouse SK, Sayar H. Does race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms? Hematol/Oncol Stem Cell Ther. 2021;15:30–38
Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. 2016;174:382–96.
Google Scholar
Yan J, Hammami MB, Wei JX, Shah N, Goldfinger M, Mantzaris I, et al. Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database. Ann Hematol. 2024;103:3543–51.
Google Scholar
Palmer A, Rauscher G, Schoen A, Burkart M, Dunton A, Au C, et al. Assessing disparities in a Chicagoland cohort of patients with myelofibrosis. Blood. 2024;144:3794.
Google Scholar
Mukhtiar VP, Gandhi OH, Bhanushali C, Mehta M, Parikh K, Shah R, et al. Chronic myeloid leukemia: impact of social and demographic disparities on survival outcomes. Blood. 2024;144:534.
Google Scholar
Ugwu C, Okere U, Obomanu E, Jones C, King S, Taneja A. CML-836: racial disparities in clinical outcomes among black and white patients with chronic myeloid leukemia: a 3- and 5-year real-world analysis. Clin Lymphoma Myeloma Leuk. 2025;25:S579.
Google Scholar
Mendizabal AM, Anderson WF, García-González P, Levine PH. Differing age patterns in chronic myeloid leukemia by racial ethnic group. J Clin Oncol. 2010;28:1577–1577.
Google Scholar
Duncombe AS, Anderson LA, James G, deVocht F, Fritschi L, Mesa R, et al. Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. Hemasphere. 2020;4:e327.
Google Scholar
Parasuraman SV, Naim AB, Paranagama DC, Thyne M, Goldberger S, Mascarenhas J, et al. Financial burden of myeloproliferative neoplasms on patients: results from the MPN landmark survey in the United States. Blood. 2015;126:5561.
Google Scholar
Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Impact of myeloproliferative neoplasms (MPNs) on patients’ overall health and productivity: results from the MPN LANDMARK SURVEY in the United States. Blood. 2014;124:3183.
Google Scholar
Goel S, Paoli C, Iurlo A, Pereria A, Efficace F, Barbui T, et al. Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. Eur J Haematol. 2017;99:36–41.
Google Scholar
Bankar A, Zhao H, Iqbal J, Coxford R, Cheung M, Mozessohn L, et al. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada. Leuk Lymphoma. 2020;61:1908–19.
Google Scholar
Álvarez-Larrán A, Ancochea A, García M, Climent F, García-Pallarols F, Angona A, et al. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol. 2014;166:911–9.
Google Scholar
Sant M, Allemani C, Tereanu C, Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.
Google Scholar
Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55:595–600.
Google Scholar
Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–97.
Google Scholar
NCI. Cancer Incidence Rates Adjusted for Reporting Delay. 2025. Available from: https://surveillance.cancer.gov/delay/.
